DeepMed Research

UNIVERSITY COLLEGE LONDON

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Private

Established: 1826-02-11

Employees: 10K

Market Cap: -

Website: http://www.ucl.ac.uk

Clinical Trials

Clinical Trial of Light Therapy for Epilepsy

Not Applicable

Conditions: Epilepsy

Interventions: Other: 100 lux
Other: Light Therapy

First Posted Date: 2009-12-09

Last Posted Date: 2009-12-09

Lead Sponsor: University College, London

Target Recruit Count: 100

Registration Number: NCT01028456

Locations: 🇬🇧
National Hospital for Neurology & Neurosurgery, London, United Kingdom

Comparison of Intra-operative Radiotherapy With Post-operative Radiotherapy for Women With Early Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer
Invasive Breast Cancer

Interventions: Device: Intrabeam
Radiation: Post-operative radiotherapy

First Posted Date: 2009-09-24

Last Posted Date: 2014-12-05

Lead Sponsor: University College, London

Target Recruit Count: 3451

Registration Number: NCT00983684

Locations: 🇬🇧
Clinical Trials Group, London, United Kingdom

Capecitabine, Irinotecan Hydrochloride, Cetuximab, and Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer

Phase 1

Completed

Conditions: Rectal Cancer

First Posted Date: 2009-09-09

Last Posted Date: 2017-10-25

Lead Sponsor: University College, London

Target Recruit Count: 82

Registration Number: NCT00972881

Locations: 🇬🇧
Cancer Research UK and University College London Cancer Trials Centre, Rhyl, Denbighshire, Wales, United Kingdom
🇬🇧
Yorkshire Regional Clinical Trials & Research Unit, Leeds, England, United Kingdom
🇬🇧
Christie Hospital, Manchester, England, United Kingdom

and more 2 locations

Gemcitabine Hydrochloride, Cyclophosphamide, Vincristine Sulfate, Prednisolone, and Rituximab in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: cyclophosphamide
Drug: gemcitabine hydrochloride
Drug: prednisolone
Drug: vincristine sulfate

First Posted Date: 2009-09-04

Last Posted Date: 2014-12-04

Lead Sponsor: University College, London

Target Recruit Count: 62

Registration Number: NCT00971763

Locations: 🇬🇧
Sussex Cancer Centre at Royal Sussex County Hospital, Brighton, England, United Kingdom
🇬🇧
Leeds General Infirmary, Leeds, England, United Kingdom
🇬🇧
Cancer Research UK and University College London Cancer Trials Centre, London, England, United Kingdom

and more 1 locations

Determining a Viral Load Threshold for Treating Cytomegalovirus (CMV)

Phase 4

Completed

Conditions: Viraemia

Interventions: Drug: ganciclovir (start when CMV PCR >200copies / ml x2)
Drug: Stop treatment when 2 levels CMV PCR <3,000 copies / ml
Other: Monitor (Treatment starts when CMV PCR >3,000 copies / ml)
Other: Monitor (Treatment stops CMV PCR <200 copies / ml x2)

First Posted Date: 2009-07-27

Last Posted Date: 2017-10-27

Lead Sponsor: University College, London

Target Recruit Count: 165

Registration Number: NCT00947141

Locations: 🇬🇧
Royal Free London NHS Foundation Trust, Royal Free Hospital, Pond Street, London, United Kingdom

PET Scan in Planning Treatment in Patients Undergoing Combination Chemotherapy For Stage IA or Stage IIA Hodgkin Lymphoma

Phase 3

Active, not recruiting

Conditions: Lymphoma

Interventions: Radiation: Involved Field Radiotherapy
Other: No further treatment

First Posted Date: 2009-07-22

Last Posted Date: 2023-11-30

Lead Sponsor: University College, London

Target Recruit Count: 602

Registration Number: NCT00943423

Locations: 🇬🇧
Christie Hospital, Manchester, England, United Kingdom

Cediranib Versus Placebo Plus Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers

Phase 2

Completed

Conditions: Biliary Tract Neoplasms

Interventions: Drug: cisplatin
Drug: gemcitabine
Drug: cediranib
Drug: Placebo

First Posted Date: 2009-07-15

Last Posted Date: 2014-10-27

Lead Sponsor: University College, London

Target Recruit Count: 124

Registration Number: NCT00939848

Locations: 🇬🇧
University College London Hospitals NHS Foundation Trust, London, United Kingdom
🇬🇧
The Christie NHS Foundation Trust, Manchester, United Kingdom

The Use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura (TTP)

Phase 2

Completed

Conditions: Thrombotic Thrombocytopenic Purpura (TTP)

Interventions: Drug: Rituximab

First Posted Date: 2009-07-10

Last Posted Date: 2023-05-16

Lead Sponsor: University College, London

Target Recruit Count: 40

Registration Number: NCT00937131

Locations: 🇬🇧
University College London Hospitals, London, United Kingdom
🇬🇧
St Bartholomew's Hospital, London, United Kingdom
🇬🇧
St Thomas Hosptial, London, United Kingdom

Dementia Early Recognition and Response in Primary Care

Phase 2

Conditions: Dementia

Interventions: Other: Educational Dementia training

First Posted Date: 2009-03-20

Last Posted Date: 2010-04-19

Lead Sponsor: University College, London

Target Recruit Count: 125

Registration Number: NCT00866099

Locations: 🇬🇧
Department of Primary Care and Population Health, London, England, United Kingdom
🇬🇧
University College London, London, Greater London, United Kingdom

ERCC1 Targeted Trial

Phase 3

Terminated

Conditions: Lung Cancer

Interventions: Drug: Cisplatin, Paclitaxel

First Posted Date: 2008-12-03

Last Posted Date: 2013-12-10

Lead Sponsor: University College, London

Target Recruit Count: 648

Registration Number: NCT00801736

Locations: 🇬🇧
University College London Hospitals, London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy